Differential Extracellular and Intracellular Concentrations of Zidovudine and Lamivudine in Semen and Plasma of HIV-1-Infected Men
- 1 June 2008
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 48 (2) , 156-162
- https://doi.org/10.1097/qai.0b013e31816de21e
Abstract
Objectives: To quantitate extracellular and intracellular zidovudine (ZDV) and lamivudine (3TC) concentrations in blood and semen of HIV-1-infected men. Design: Nonblind, single-center, open-label pharmacokinetic (PK) study in 14 subjects receiving ZDV plus 3TC. Methods: Paired blood and semen samples were obtained during 1 intensive visit and 3 single time point visits over 2 weeks. Extracellular ZDV and 3TC concentrations were measured in blood plasma (BP) and seminal plasma (SP), and intracellular ZDV and 3TC triphosphate (TP) concentrations were measured in isolated mononuclear cells using validated methods. HIV-1 RNA was measured in blood and semen. PK parameters were estimated using noncompartmental analysis. Results: Median (interquartile range [IQR]) SP/BP area under the time-concentration curve over the 12-hour dosing interval (AUC0-12h) ratios for ZDV and 3TC were 2.28 (1.48 to 2.97) and 6.67 (4.10 to 9.14), respectively, whereas individual SP/BP concentration ratios ranged from 1.9 to 91.4. Intracellular median (IQR) SP/BP AUC0-12h ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37) and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11 to 2.9. HIV-1 RNA was undetectable in both compartments. Conclusions: ZDV and 3TC SP exposures are 2- to 6-fold greater than BP exposures. Seminal ZDV-TP exposures are ∼40% of those found in peripheral blood mononuclear cells (PBMCs), whereas 3TC-TP exposures are similar to PBMC exposures. PK variability makes individual SP/BP ratios a suboptimal surrogate for genital tract exposure.Keywords
This publication has 52 references indexed in Scilit:
- The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital TractJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisAIDS, 2007
- Long‐Term Persistence of Transmitted HIV Drug Resistance in Male Genital Tract Secretions: Implications for Secondary TransmissionThe Journal of Infectious Diseases, 2007
- HIV‐1 Drug Resistance in Variants from the Female Genital Tract and PlasmaThe Journal of Infectious Diseases, 2007
- Cervical Shedding of HIV-1 RNA Among Women With Low Levels of Viremia While Receiving Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsAIDS, 2003
- Effects of Formulation and Dosing Strategy on Amprenavir Concentrations in the Seminal Plasma of Human Immunodeficiency Virus Type 1–Infected MenClinical Infectious Diseases, 2002
- Nucleoside Analogues Achieve High Concentrations in Seminal Plasma: Relationship between Drug Concentration and Virus BurdenThe Journal of Infectious Diseases, 1999
- Detection Of Drug Resistance Mutations In The Human Immunodeficiency Virus Type I (HIV-I) pol Gene: Differences In Semen And Blood HIV-I RNA And Proviral DNAThe Journal of Infectious Diseases, 1994
- Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.Journal of Clinical Investigation, 1993